Bayesian Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bayesian Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-31,000	Closed	-$128K	–	987
2022 Q2	$128K	Buy	31,000 +8,240	+36%	+$35.6K	0.02%	664
2022 Q1	$132K	Buy	+22,760	New	+$135K	0.02%	684
2020 Q3	–	Sell	-53,700	Closed	-$481K	–	674
2020 Q2	$481K	Sell	53,700 -56,300	-51%	-$522K	0.11%	243
2020 Q1	$701K	Buy	+110,000	New	+$816K	0.15%	205
2018 Q3	–	Sell	-13,015	Closed	-$185K	–	776
2018 Q2	$185K	Sell	13,015 -17,393	-57%	-$289K	0.04%	529
2018 Q1	$578K	Buy	+30,408	New	+$650K	0.15%	239

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bayesian Capital Management's SGMO Position: Q3 2022 in Review

Bayesian Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2022, closing a stake of 31,000 shares — an estimated $128K sold.

Bayesian Capital Management first reported a position in SGMO in Q1 2018 and held it in 6 quarters. The position peaked at $701K in Q1 2020. 197 funds tracked by Wall St. Rank hold SGMO as of Q3 2022.

Bayesian Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2022 after selling out during the quarter.
Bayesian Capital Management sold 31,000 SANGAMO THERAPEUTICS INC shares in Q3 2022, an estimated $128K.
Bayesian Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 6 quarters.
Bayesian Capital Management's SANGAMO THERAPEUTICS INC position peaked at $701K in Q1 2020.
197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2022.

Based on Bayesian Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.